OPNT - Opiant shares rise on OPNT003 opioid overdose study results

Opiant Pharmaceuticals (OPNT) announces positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.Shares up more than 13% post market.The data showed that nasal nalmefene achieved "significantly higher" plasma concentrations compared to an intramuscular injection (p<0.0001).The time for nasal nalmefene to achieve maximum plasma concentrations (Tmax) was consistent with data from the previously completed pilot study (~15 minutes).The company expects to post top-line data from the study in the fourth quarter of 2021.

For further details see:

Opiant shares rise on OPNT003 opioid overdose study results